We announced our financial results for the three first months of 2024.
Download financial workbook (xlsx)
Investor presentation (iPaper)
We announced our financial results for the six first months of 2024.
Download financial workbook (xlsx)
Investor presentation (iPaper)
Q4 and full-year 2024 financial results will be published 5 February 2025.
Our CEO, Lars Fruergaard Jørgensen, presented at the Annual J.P. Morgan Healthcare Conference in San Francisco, USA on 09 January.
Our Capital Markets Day took place on the 7th of March.
Novo Nordisk Executive Management and other members of senior management provided a full review of our strategy, operations and financial targets.
We held our Annual General Meeting on 21 March 2024 at 14:00 CET.
Watch recordings and download documents from our latest Annual General Meeting.
Q4
Novo Nordisk A/S announced financial results for the full year
of 2023:
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q3
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q2
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q1
Download financial workbook (xlsx)
Investor presentation (iPaper)
Annual General Meeting
23 March 2023
Annual General
Meeting (webcast)
Generalforsamling
(webcast)
See
previous AGM documentation
R&D investor call in relation to ADA 2023
26 June 2023
Presentation
(Webcast)
Download
presentation (pdf)
American Heart Association (AHA) conference
11-12
November 2023
Q4
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
Q3
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q2
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q1
Download financial workbook (xlsx)
Investor presentation (iPaper)
Capital Markets Day
03 March 2022
Watch the presentations and get the slides from the Novo Nordisk Capital Markets Day
Annual General Meeting
24 March 2022
Annual General Meeting (webcast)
See previous Annual General Meeting documentation
Investor event (ADA 82nd Scientific Sessions)
5 June 2022
Novo Nordisk investor and analyst event at ADA 2022 (Webcast)
Q4
Download company announcement (pdf)
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q3
Download company announcement (pdf)
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q2
Download company announcement (pdf)
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q1
Download company announcement (pdf)
Download financial workbook (xlsx)
Investor presentation (iPaper)
Conference call on supply situation for Wegovy®
20 December 2021
R&D investor call
28 June 2021
Approval of Wegovy™ in the US
7 June 2021
International Operations call
21 May 2021
Annual General Meeting
25 March 2021
Q4
Download company announcement (pdf)
Download financial workbook (xlsx)
Watch Novo Nordisk CEO reflect on the full year results 2021 (video)
Investor presentation (iPaper)
Earnings conference call (webcast)
London
earnings conference call (webcast)
Q3
Download company Announcement (pdf)
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q2
Download company announcement (pdf)
Download financial workbook (xlsx)
Investor presentation (iPaper)
Earnings conference call (webcast)
London earnings conference call (webcast)
Q1
Download company announcement (pdf)
Download financial workbook (xlsx)
Investor presentation (iPaper)
Decision to enter phase 3 development in Alzheimer’s disease and
GLP-1 R&D strategy update
16 December 2020
ESG conference call
30 November 2020
Download the ESG presentation (pdf)
Novo Nordisk raises sales and operating profit outlook for 2020
9 October 2020
R&D investor presentation
19 June 2020
Annual General Meeting
26 March 2020
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
Investors
Share price
{{priceData.date}} {{priceData.time}}